Filed under: General Problems | Leave a Comment »
Payvider: Health Insurance Payer and Healthcare Provider Combination Explained
Posted on April 22, 2024 by Pharmaciststeve
APDF goes to Washington DC to lobby members of Congress
Posted on April 22, 2024 by Pharmaciststeve
Filed under: General Problems | 4 Comments »
Two Years And $113 Billion Later, D.C.’s ‘America Last’ Crew Has No Plan For Ending The Russia-Ukraine War
Posted on April 22, 2024 by Pharmaciststeve
When you look into the rearview mirror, “we” seem to like to be “in a war”. The last time that we won a war was 1945 – almost 80 years ago – and that took TWO A-BOMBS. When Obama came to office we were 9 trillion in debt and when he left we were ~ […]
Filed under: General Problems | 2 Comments »
Federal Agencies Launch Portal for Public Reporting of Anticompetitive Practices in the Health Care Sector
Posted on April 22, 2024 by Pharmaciststeve
Federal Agencies Launch Portal for Public Reporting of Anticompetitive Practices in the Health Care Sector https://www.ftc.gov/news-events/news/press-releases/2024/04/federal-agencies-launch-portal-public-reporting-anticompetitive-practices-health-care-sector Today, the Federal Trade Commission, Justice Department, and the U.S. Department of Health and Human Services (HHS) launched an easily accessible online portal for the public to report health care practices that may harm competition. The online portal, HealthyCompetition.gov, […]
Filed under: General Problems | Leave a Comment »
PBM rebate schemes to suppress biosimilar Humira cost patients $6B, IQVIA analysis finds
Posted on April 22, 2024 by Pharmaciststeve
PBM rebate schemes to suppress biosimilar Humira cost patients $6B, IQVIA analysis finds https://drugstorenews.com/pbm-rebate-schemes-suppress-biosimilar-humira-cost-patients-6b-iqvia-analysis-finds The Biosimilars Council released a new analysis by IQVIA that reveals a PBM strategy to protect $2 billion in profits by “strangling” the biosimilar market and preventing savings for patients. The Biosimilars Council, a trade association representing manufacturers of biosimilar medicines, […]
Filed under: General Problems | 1 Comment »